Google
Trusted Resources: News & Events
Latest announcements and gatherings
Spectra Optia Device Save Way to Treat Sickle Cell While Using Less Blood Cell Packs, Study Finds
The blood-separation device Spectra Optia, which has the ability to remove abnormal red blood cells from sickle cell patients, can efficiently and safely replace these cells with healthy red blood cells from donors, a study reports.
The therapeutic tool also uses less red blood cell units than regular transfusion techniques, i.e., without the removal of abnormal red blood cells (RBCs).
The study, “Automatic depletion with Spectra Optia allows a safe 16% reduction of red blood cell pack consumption in exchanged sickle cell anemia patients,” was published in the journal Transfusion.
Sickle-cell anemia results from an abnormality in the oxygen-carrying protein hemoglobin found in red blood cells. Cells become sticky and rigid, with a sickle or crescent moon shape, and are prone to getting trapped in small vessels, stopping the blood from circulating and causing painful vaso-occlusive crisis.
+myBinderRelated Content
-
Early clinical trial data show gene therapy reversing sickle cell anemiaAfter over a decade of preclin...
-
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell DiseaseImara Inc. today announced it will repor...
-
Gabapentin for Pain in Sickle Cell Disease: Results of a Randomized Phase ll Clinical TrialBackground: Pain in sickle cell disease...
-
Fetal Haemoglobin in Sickle-cell Disease: From Genetic Epidemiology to New Therapeutic StrategiesSickle-cell disease affects millions of ...
-
Phase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCDGlycoMimetics, in collaboration with Pfi...
-
100 Years But Only One Drug: Sickle Cell Patients Wait For HelpLast week, 100,000 Americans with sickle...
-
GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.